查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2019784

眼科疾病治疗市场规模、份额、成长率及全球产业分析：按类型、应用和地区划分，并预测至2026-2034年

Ophthalmic Disease Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 180 Pages | 商品交期: 请询问到货日

价格

眼科疾病治疗市场成长要素

受眼科疾病率上升和对先进治疗方案需求不断增长的推动，全球眼科药物市场正稳步增长。预计到2025年，该市场规模将达到400.9亿美元，2026年将成长至426.1亿美元，到2034年将达到715.8亿美元。这一增长反映了眼科药物研发的持续进步以及全球眼部健康意识的不断提高。

眼科药物包括用于治疗青光眼、干眼症、视网膜疾病和眼部感染疾病等疾病的药物和治疗方法。这些疾病负担日益加重，尤其是在高龄化社会中，是推动市场扩张的主要因素。

市场趋势

塑造市场格局的关键趋势之一是对先进药物输送系统的日益重视。传统的眼科治疗常面临药物吸收率低、药物快速从体内排放等挑战。为了克服这些挑战，各公司正投资研发创新解决方案，例如基于奈米技术的製剂、缓释植入和药物缓释隐形眼镜。

此外，基因疗法和生物製药的应用日益普及。这些先进治疗方法提供标靶治疗方案，改善患者预后并减少给药频率。人工智慧（AI）在诊断和治疗方案製定中的应用也推动了市场的发展。

市场成长要素

眼科疾病治疗市场的主要驱动力是眼科疾病发生率的上升。由于人口老化和生活方式的改变，青光眼和老龄化黄斑部病变等疾病变得越来越常见。萤幕使用时间的增加和环境因素也是导致视力问题的原因。

另一个主要因素是研发投入的增加。製药公司正积极研发新药和新治疗方法，以满足尚未满足的医疗需求。临床试验和监管核准的增加正在加速产品上市，并拓宽治疗选择。

此外，医疗保健支出增加和眼科医疗保健服务可近性的提高，导致全球诊断和治疗率上升，从而进一步促进了市场成长。

抑制因子

儘管市场成长前景强劲，但也面临许多挑战。生物製药和先进治疗方法的高成本仍然是一大障碍，尤其是在发展中地区。许多患者难以负担这些治疗费用，导致治疗顺从性降低。

此外，新兴国家医疗卫生基础设施匮乏，以及公众意识不足，阻碍了早期诊断和治疗。这些因素造成了患者群体与现有治疗方案之间的差距，从而减缓了整体市场渗透率。

細項分析

按药物分类

市场区隔包括抗发炎药、感染疾病、抗血管内皮生长因子（VEGF）药、抗青光眼药及其他药物。预计到2026年，抗发炎药物将占据较大的市场份额，这主要得益于对治疗方法眼部发炎和过敏药物的高需求。同时，随着视网膜疾病病例的增加，抗VEGF疗法预计将快速增长。

按剂型

根据剂型，市场包括液体製剂、固态和半固态製剂。由于半固体製剂具有更长的药物停留时间和更高的疗效，预计到2026年，半固态製剂将占据市场主导地位，市场份额将达到79.59%。液体製剂因其给药方便仍被广泛使用。

疾病特异性

受糖尿病视网膜病变和老龄化黄斑部病变病例不断增加的影响，视网膜疾病预计将在2026年成为该细分市场的主要驱动因素，占33.94%的市场份额。干眼症和青光眼细分市场也在稳定成长。

透过分销管道

受数位化进步和购药便利性提高的推动，预计到 2026 年，零售药局和线上药局将主导市场，占据 89.97% 的市场份额。

区域趋势

北美占最大的市场份额，预计到 2025 年将达到 43.37%（市场规模为 173.9 亿美元），到 2026 年将扩大到 184.8 亿美元。该地区受益于强大的医疗保健基础设施、较高的健康意识和新药认证。

欧洲是第二大市场，主要受人口老化和眼科疾病率上升的驱动。亚太地区预计将成为成长最快的地区，这得益于医疗保健投资的增加和患者意识的提高。

拉丁美洲、中东和非洲的市场正在逐步扩大，这得益于医疗保健服务的改善和先进治疗方法的广泛应用。

目录

第一章：引言

第二章执行摘要

第三章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第四章：主要考虑因素

  • 主要眼科疾病盛行率：依主要国家划分，2025 年
  • 主要企业管道分析
  • 主要企业专利概览
  • 产业重大发展动态－併购与合作
  • 主要国家的监管状况
  • 主要国家的还款状况
  • 新冠疫情对市场的影响

第五章：2021-2034年全球眼科疾病治疗市场分析、洞察与预测

  • 市场分析、洞察与预测：按药物类别划分
    • 抗发炎药
    • 抗感染药物
    • Anti-VEGF
    • 青光眼药物
      • β阻断剂
      • 前列腺素类似物
      • α肾上腺素促效剂
      • 碳酸酐酶抑制剂
      • 同时服用的药物
      • 其他的
    • 其他的
  • 市场分析、洞察与预测：按剂型划分
    • 固体的
    • 液体
    • 半固态製剂
  • 市场分析、洞察与预测：按适用疾病分类。
    • 青光眼
      • 开放性青光眼
      • 隅角闭锁性青光眼
      • 其他的
    • 干眼症
    • 视网膜疾病
      • 糖尿病黄斑部水肿（DME）
      • 黄斑部病变（AMD）
      • 糖尿病视网膜病变（DR）
      • 视网膜静脉阻塞（RVO）
      • 其他的
    • 过敏及感染疾病
    • 其他的
  • 市场分析、洞察与预测：按分销管道划分
    • 医院药房
    • 实体店和网路药局
  • 市场分析、洞察与预测：按地区划分
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美眼科疾病治疗市场分析、洞察与预测（2021-2034年）

  • 国家
    • 我们
    • 加拿大

第七章：欧洲眼科疾病治疗市场分析、洞察与预测（2021-2034年）

  • 国家
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪地那维亚
    • 其他欧洲国家

第八章：亚太眼科疾病治疗市场分析、洞察与预测（2021-2034年）

  • 国家
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 东南亚
    • 其他亚太国家

第九章：拉丁美洲眼科疾病治疗市场分析、洞察与预测（2021-2034年）

  • 国家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第十章：中东和非洲眼科疾病治疗市场分析、洞察与预测（2021-2034年）

  • 国家
    • GCC
    • 南非
    • 其他中东和非洲国家

第十一章 竞争分析

  • 全球市占率分析（2025 年）
  • 公司简介
    • Viatris Inc.
    • Novartis AG
    • AbbVie Inc.
    • F. Hoffmann-La Roche Ltd.
    • Regeneron Pharmaceuticals, Inc.
    • Santen Pharmaceutical Co., Ltd.
    • Bayer AG
    • Bausch & Lomb Incorporated
    • Merck KGaA
Product Code: FBI100441

Growth Factors of ophthalmic disease therapeutics Market

The global ophthalmic disease therapeutics market is witnessing steady growth driven by the increasing prevalence of eye-related disorders and rising demand for advanced treatment solutions. The market was valued at USD 40.09 billion in 2025 and is expected to grow to USD 42.61 billion in 2026, reaching USD 71.58 billion by 2034. This growth reflects continuous advancements in ophthalmic drug development and increasing awareness regarding eye health worldwide.

Ophthalmic therapeutics include drugs and treatments designed to manage conditions such as glaucoma, dry eye disease, retinal disorders, and ocular infections. The rising burden of these diseases, especially among the aging population, is significantly contributing to the expansion of the market.

Market Trends

A key trend shaping the market is the growing focus on advanced drug delivery systems. Traditional eye treatments often face limitations due to poor drug absorption and rapid elimination. To overcome these challenges, companies are investing in innovative solutions such as nanotechnology-based formulations, sustained-release implants, and drug-eluting contact lenses.

Additionally, the adoption of gene therapies and biologics is increasing. These advanced therapies offer targeted treatment options, improving patient outcomes and reducing the frequency of administration. The integration of artificial intelligence in diagnosis and treatment planning is also supporting the market's evolution.

Market Growth Drivers

The primary factor driving the ophthalmic disease therapeutics market is the rising prevalence of eye disorders. Conditions such as glaucoma and macular degeneration are becoming more common due to aging populations and lifestyle changes. Increasing screen time and environmental factors further contribute to vision-related problems.

Another major driver is the growing investment in research and development. Pharmaceutical companies are actively developing novel drugs and therapies to address unmet medical needs. The increasing number of clinical trials and regulatory approvals is accelerating product launches and expanding treatment options.

Moreover, rising healthcare expenditure and improved access to eye care services are boosting diagnosis and treatment rates globally, further supporting market growth.

Restraining Factors

Despite strong growth prospects, the market faces certain challenges. The high cost of biologics and advanced therapies remains a significant barrier, particularly in developing regions. Many patients struggle with affordability, leading to lower treatment adherence.

Additionally, lack of awareness and limited access to healthcare infrastructure in emerging economies restricts early diagnosis and treatment. These factors create a gap between the patient population and available therapeutic solutions, slowing overall market adoption.

Segmentation Analysis

By Drug Class

The market is segmented into anti-inflammatory, anti-infectives, anti-VEGF, anti-glaucoma, and others. The anti-inflammatory segment holds a significant share in 2026, driven by high demand for treatments addressing ocular inflammation and allergies. Meanwhile, anti-VEGF therapies are expected to grow rapidly due to increasing cases of retinal diseases.

By Dosage Form

Based on dosage form, the market includes liquid, solid, and semisolid formulations. The semisolid segment dominates with 79.59% share in 2026, owing to its prolonged drug retention and effectiveness. Liquid forms remain widely used due to ease of administration.

By Disease Indication

Retinal diseases lead the segment with a 33.94% market share in 2026, driven by rising cases of diabetic retinopathy and macular degeneration. Dry eye disease and glaucoma segments are also expanding steadily.

By Distribution Channel

Retail and online pharmacies dominate the market with 89.97% share in 2026, supported by increasing digital adoption and convenience in purchasing medications.

Regional Insights

North America holds the largest share, accounting for 43.37% in 2025, with a market value of USD 17.39 billion, rising to USD 18.48 billion in 2026. The region benefits from strong healthcare infrastructure, high awareness, and continuous product approvals.

Europe follows as the second-largest market, driven by an aging population and increasing prevalence of eye diseases. Asia Pacific is expected to witness the fastest growth due to rising healthcare investments and growing patient awareness.

Latin America and the Middle East & Africa are gradually expanding, supported by improving healthcare access and increasing adoption of advanced therapies.

Conclusion

The ophthalmic disease therapeutics market is set for robust growth from USD 40.09 billion in 2025 to USD 71.58 billion by 2034, driven by rising prevalence of eye disorders, technological advancements, and increasing R&D activities. While high treatment costs and limited awareness in emerging regions pose challenges, ongoing innovations and expanding healthcare access are expected to bridge these gaps. Overall, the market presents significant opportunities for stakeholders, with continuous advancements shaping the future of eye care globally.

Segmentation By Drug Class

  • Anti-inflammatory
  • Anti-infectives
  • Anti-VEGF
  • Anti-glaucoma
    • Beta Blockers
    • Prostaglandins Analogs
    • Alpha Adrenergic Agonists
    • Carbonic Anhydrase Inhibitors
    • Combination Drugs
    • Others
  • Others

By Dosage Form

  • Solid
  • Liquid
  • Semisolid

By Disease Indication

  • Glaucoma
    • Open Angle Glaucoma
    • Angle Closure Glaucoma
    • Others
  • Dry Eye Disease
  • Retinal Diseases
    • Diabetic Macular Edema (DME)
    • Macular Degeneration (AMD)
    • Diabetic Retinopathy (DR)
    • Retinal Vein Occlusion (RVO)
    • Others
  • Allergy & Infections
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail & Online Pharmacies

By Region

  • North America (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Major Ophthalmic Diseases, in Key Countries/ Region, 2025
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Patent Snapshot, By Key Players
  • 4.4. Key Industry Developments - Merges, Acquisitions and Partnerships
  • 4.5. Regulatory Scenario for Key Countries
  • 4.6. Reimbursement Scenario for Key Countries
  • 4.7. Impact of COVID-19 on the Market

5. Global Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Anti-inflammatory
    • 5.1.2. Anti-infectives
    • 5.1.3. Anti-VEGF
    • 5.1.4. Anti-glaucoma
      • 5.1.4.1. Beta Blockers
      • 5.1.4.2. Prostaglandins Analogs
      • 5.1.4.3. Alpha Adrenergic Agonists
      • 5.1.4.4. Carbonic Anhydrase Inhibitors
      • 5.1.4.5. Combination Drugs
      • 5.1.4.6. Others
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 5.2.1. Solid
    • 5.2.2. Liquid
    • 5.2.3. Semisolid
  • 5.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.3.1. Glaucoma
      • 5.3.1.1. Open Angle Glaucoma
      • 5.3.1.2. Angle Closure Glaucoma
      • 5.3.1.3. Others
    • 5.3.2. Dry Eye Disease
    • 5.3.3. Retinal Diseases
      • 5.3.3.1. Diabetic Macular Edema (DME)
      • 5.3.3.2. Macular Degeneration (AMD)
      • 5.3.3.3. Diabetic Retinopathy (DR)
      • 5.3.3.4. Retinal Vein Occlusion (RVO)
      • 5.3.3.5. Others
    • 5.3.4. Allergy & Infections
    • 5.3.5. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Retail & Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Anti-inflammatory
    • 6.1.2. Anti-infectives
    • 6.1.3. Anti-VEGF
    • 6.1.4. Anti-glaucoma
      • 6.1.4.1. Beta Blockers
      • 6.1.4.2. Prostaglandins Analogs
      • 6.1.4.3. Alpha Adrenergic Agonists
      • 6.1.4.4. Carbonic Anhydrase Inhibitors
      • 6.1.4.5. Combination Drugs
      • 6.1.4.6. Others
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 6.2.1. Solid
    • 6.2.2. Liquid
    • 6.2.3. Semisolid
  • 6.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.3.1. Glaucoma
      • 6.3.1.1. Open Angle Glaucoma
      • 6.3.1.2. Angle Closure Glaucoma
      • 6.3.1.3. Others
    • 6.3.2. Dry Eye Disease
    • 6.3.3. Retinal Diseases
      • 6.3.3.1. Diabetic Macular Edema (DME)
      • 6.3.3.2. Macular Degeneration (AMD)
      • 6.3.3.3. Diabetic Retinopathy (DR)
      • 6.3.3.4. Retinal Vein Occlusion (RVO)
      • 6.3.3.5. Others
    • 6.3.4. Allergy & Infections
    • 6.3.5. Others
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Retail & Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Anti-inflammatory
    • 7.1.2. Anti-infectives
    • 7.1.3. Anti-VEGF
    • 7.1.4. Anti-glaucoma
      • 7.1.4.1. Beta Blockers
      • 7.1.4.2. Prostaglandins Analogs
      • 7.1.4.3. Alpha Adrenergic Agonists
      • 7.1.4.4. Carbonic Anhydrase Inhibitors
      • 7.1.4.5. Combination Drugs
      • 7.1.4.6. Others
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 7.2.1. Solid
    • 7.2.2. Liquid
    • 7.2.3. Semisolid
  • 7.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.3.1. Glaucoma
      • 7.3.1.1. Open Angle Glaucoma
      • 7.3.1.2. Angle Closure Glaucoma
      • 7.3.1.3. Others
    • 7.3.2. Dry Eye Disease
    • 7.3.3. Retinal Diseases
      • 7.3.3.1. Diabetic Macular Edema (DME)
      • 7.3.3.2. Macular Degeneration (AMD)
      • 7.3.3.3. Diabetic Retinopathy (DR)
      • 7.3.3.4. Retinal Vein Occlusion (RVO)
      • 7.3.3.5. Others
    • 7.3.4. Allergy & Infections
    • 7.3.5. Others
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail & Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.5.1. U.K
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Anti-inflammatory
    • 8.1.2. Anti-infectives
    • 8.1.3. Anti-VEGF
    • 8.1.4. Anti-glaucoma
      • 8.1.4.1. Beta Blockers
      • 8.1.4.2. Prostaglandins Analogs
      • 8.1.4.3. Alpha Adrenergic Agonists
      • 8.1.4.4. Carbonic Anhydrase Inhibitors
      • 8.1.4.5. Combination Drugs
      • 8.1.4.6. Others
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 8.2.1. Solid
    • 8.2.2. Liquid
    • 8.2.3. Semisolid
  • 8.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.3.1. Glaucoma
      • 8.3.1.1. Open Angle Glaucoma
      • 8.3.1.2. Angle Closure Glaucoma
      • 8.3.1.3. Others
    • 8.3.2. Dry Eye Disease
    • 8.3.3. Retinal Diseases
      • 8.3.3.1. Diabetic Macular Edema (DME)
      • 8.3.3.2. Macular Degeneration (AMD)
      • 8.3.3.3. Diabetic Retinopathy (DR)
      • 8.3.3.4. Retinal Vein Occlusion (RVO)
      • 8.3.3.5. Others
    • 8.3.4. Allergy & Infections
    • 8.3.5. Others
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail & Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Anti-inflammatory
    • 9.1.2. Anti-infectives
    • 9.1.3. Anti-VEGF
    • 9.1.4. Anti-glaucoma
      • 9.1.4.1. Beta Blockers
      • 9.1.4.2. Prostaglandins Analogs
      • 9.1.4.3. Alpha Adrenergic Agonists
      • 9.1.4.4. Carbonic Anhydrase Inhibitors
      • 9.1.4.5. Combination Drugs
      • 9.1.4.6. Others
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 9.2.1. Solid
    • 9.2.2. Liquid
    • 9.2.3. Semisolid
  • 9.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.3.1. Glaucoma
      • 9.3.1.1. Open Angle Glaucoma
      • 9.3.1.2. Angle Closure Glaucoma
      • 9.3.1.3. Others
    • 9.3.2. Dry Eye Disease
    • 9.3.3. Retinal Diseases
      • 9.3.3.1. Diabetic Macular Edema (DME)
      • 9.3.3.2. Macular Degeneration (AMD)
      • 9.3.3.3. Diabetic Retinopathy (DR)
      • 9.3.3.4. Retinal Vein Occlusion (RVO)
      • 9.3.3.5. Others
    • 9.3.4. Allergy & Infections
    • 9.3.5. Others
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail & Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Anti-inflammatory
    • 10.1.2. Anti-infectives
    • 10.1.3. Anti-VEGF
    • 10.1.4. Anti-glaucoma
      • 10.1.4.1. Beta Blockers
      • 10.1.4.2. Prostaglandins Analogs
      • 10.1.4.3. Alpha Adrenergic Agonists
      • 10.1.4.4. Carbonic Anhydrase Inhibitors
      • 10.1.4.5. Combination Drugs
      • 10.1.4.6. Others
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 10.2.1. Solid
    • 10.2.2. Liquid
    • 10.2.3. Semisolid
  • 10.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.3.1. Glaucoma
      • 10.3.1.1. Open Angle Glaucoma
      • 10.3.1.2. Angle Closure Glaucoma
      • 10.3.1.3. Others
    • 10.3.2. Dry Eye Disease
    • 10.3.3. Retinal Diseases
      • 10.3.3.1. Diabetic Macular Edema (DME)
      • 10.3.3.2. Macular Degeneration (AMD)
      • 10.3.3.3. Diabetic Retinopathy (DR)
      • 10.3.3.4. Retinal Vein Occlusion (RVO)
      • 10.3.3.5. Others
    • 10.3.4. Allergy & Infections
    • 10.3.5. Others
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail & Online Pharmacies
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Viatris Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Novartis AG
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. AbbVie Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. F. Hoffmann-La Roche Ltd.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Regeneron Pharmaceuticals, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Santen Pharmaceutical Co., Ltd.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Bayer AG
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Bausch & Lomb Incorporated
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Merck KGaA
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2021-2034
  • Table 3: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034
  • Table 4: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 5: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2021-2034
  • Table 6: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2021-2034
  • Table 7: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 9: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 10: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2021-2034
  • Table 11: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034
  • Table 12: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 13: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2021-2034
  • Table 14: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2021-2034
  • Table 15: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 17: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 18: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2021-2034
  • Table 19: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034
  • Table 20: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 21: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2021-2034
  • Table 22: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2021-2034
  • Table 23: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 25: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 26: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2021-2034
  • Table 27: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034
  • Table 28: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 29: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2021-2034
  • Table 30: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2021-2034
  • Table 31: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 32: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 33: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 34: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2021-2034
  • Table 35: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034
  • Table 36: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 37: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2021-2034
  • Table 38: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2021-2034
  • Table 39: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 40: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 41: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 42: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2021-2034
  • Table 43: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034
  • Table 44: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 45: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2021-2034
  • Table 46: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2021-2034
  • Table 47: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 48: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Ophthalmic Disease Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2025 & 2034
  • Figure 4: Global Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2025 & 2034
  • Figure 5: Global Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Ophthalmic Disease Therapeutics Market Value (USD billion), by Region, 2025 & 2034
  • Figure 7: North America Ophthalmic Disease Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 8: North America Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 9: North America Ophthalmic Disease Therapeutics Market Value (USD billion), by Dosage Form, 2025 & 2034
  • Figure 10: North America Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2025
  • Figure 11: North America Ophthalmic Disease Therapeutics Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 12: North America Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2025
  • Figure 13: North America Ophthalmic Disease Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Ophthalmic Disease Therapeutics Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Ophthalmic Disease Therapeutics Market Value Share (%), By Country, 2025
  • Figure 17: Europe Ophthalmic Disease Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 18: Europe Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 19: Europe Ophthalmic Disease Therapeutics Market Value (USD billion), by Dosage Form, 2025 & 2034
  • Figure 20: Europe Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2025
  • Figure 21: Europe Ophthalmic Disease Therapeutics Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 22: Europe Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2025
  • Figure 23: Europe Ophthalmic Disease Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Ophthalmic Disease Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Ophthalmic Disease Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Ophthalmic Disease Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 28: Asia Pacific Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 29: Asia Pacific Ophthalmic Disease Therapeutics Market Value (USD billion), by Dosage Form, 2025 & 2034
  • Figure 30: Asia Pacific Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2025
  • Figure 31: Asia Pacific Ophthalmic Disease Therapeutics Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 32: Asia Pacific Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2025
  • Figure 33: Asia Pacific Ophthalmic Disease Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Ophthalmic Disease Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Ophthalmic Disease Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Ophthalmic Disease Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 38: Latin America Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 39: Latin America Ophthalmic Disease Therapeutics Market Value (USD billion), by Dosage Form, 2025 & 2034
  • Figure 40: Latin America Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2025
  • Figure 41: Latin America Ophthalmic Disease Therapeutics Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 42: Latin America Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2025
  • Figure 43: Latin America Ophthalmic Disease Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Ophthalmic Disease Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Ophthalmic Disease Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Ophthalmic Disease Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 48: Middle East & Africa Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 49: Middle East & Africa Ophthalmic Disease Therapeutics Market Value (USD billion), by Dosage Form, 2025 & 2034
  • Figure 50: Middle East & Africa Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2025
  • Figure 51: Middle East & Africa Ophthalmic Disease Therapeutics Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 52: Middle East & Africa Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2025
  • Figure 53: Middle East & Africa Ophthalmic Disease Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Ophthalmic Disease Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Ophthalmic Disease Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Ophthalmic Disease Therapeutics Market Share (%), By Company, 2025